Xencor (NASDAQ:XNCR) Reaches New 12-Month Low – What’s Next?

Xencor, Inc. (NASDAQ:XNCR) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $12.69 and last traded at $12.89, with a volume of 723182 shares traded. The stock had previously closed at $12.87.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. StockNews.com lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Friday. Wells Fargo & Company reduced their target price on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Finally, Piper Sandler raised shares of Xencor from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $20.00 to $30.00 in a research report on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $34.38.

Xencor Price Performance

The stock’s 50-day moving average is $17.36 and its 200-day moving average is $20.47. The firm has a market cap of $912.34 million, a P/E ratio of -4.03 and a beta of 0.74. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. The business had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. As a group, equities analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Institutional Investors Weigh In On Xencor

Several institutional investors and hedge funds have recently made changes to their positions in XNCR. GAMMA Investing LLC lifted its position in Xencor by 31.0% during the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 508 shares in the last quarter. KBC Group NV lifted its position in Xencor by 26.0% during the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 813 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. lifted its position in Xencor by 8.5% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 949 shares in the last quarter. Sterling Capital Management LLC lifted its position in Xencor by 732.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,040 shares in the last quarter. Finally, Summit Investment Advisors Inc. lifted its position in Xencor by 22.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 1,282 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.